Terms: = Breast cancer AND PPFIBP1, L2, 8496, ENSG00000110841, hSGT2, hSgt2p
262 results:
1. pDNA-tachyplesin treatment stimulates the immune system and increases the probability of apoptosis in MC4-L2 tumor cells.
Mahmoudi-Filabadi F; Doosti A
Amino Acids; 2024 May; 56(1):34. PubMed ID: 38691208
[TBL] [Abstract] [Full Text] [Related]
2. [Real-time localization for port-implanted catheter tip by echocardiographic guidance].
Guo LJ; Bai YZ; Li ZY; Zhao PL; Luo B
Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(14):1184-1187. PubMed ID: 38583051
[TBL] [Abstract] [Full Text] [Related]
3. Obesity correlates with the immunosuppressive ILC2s-MDSCs axis in advanced breast cancer.
Liu W; Li B; Liu D; Zhao B; Sun G; Ding J
Immun Inflamm Dis; 2024 Mar; 12(3):e1196. PubMed ID: 38501542
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic implication of novel immune-related signature in breast cancer.
Chen B; Wu H; Fang Y; Huang G; Guo C; Chen C; He L; Chen Z; Hou X; Li C; Wu J
Medicine (Baltimore); 2024 Feb; 103(6):e37065. PubMed ID: 38335435
[TBL] [Abstract] [Full Text] [Related]
5. sPD-L1 and sPD-L2 in plasma of patients with lung cancer and their clinical significance.
Han S; Zhang Y; Yuan J; Wu Y; Zhou Y; Zhou Y; Li X; Zhou S
Cytokine; 2024 Apr; 176():156532. PubMed ID: 38330638
[TBL] [Abstract] [Full Text] [Related]
6. Cu(II) flavonoids as potential photochemotherapeutic agents.
Das N; Bora B; Upadhyay A; Das D; Bera A; Goswami TK
Dalton Trans; 2024 Feb; 53(7):3316-3329. PubMed ID: 38260975
[TBL] [Abstract] [Full Text] [Related]
7. "Heterogeneity of treatment effect on patients' long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer.".
Pala L; Sala I; Pagan E; De Pas T; Zattarin E; Catania C; Cocorocchio E; Rossi G; Laszlo D; Ceresoli G; Canzian J; Valenzi E; Bagnardi V; Conforti F
Breast; 2024 Feb; 73():103672. PubMed ID: 38244459
[TBL] [Abstract] [Full Text] [Related]
8. Comparative analysis of deep learning methods for lesion detection on full screening mammography.
Ribeiro RF; Torres HR; Oliveira B; Morais P; Vilaca JL
Annu Int Conf IEEE Eng Med Biol Soc; 2023 Jul; 2023():1-4. PubMed ID: 38082575
[TBL] [Abstract] [Full Text] [Related]
9. Euphorbia factor L2 suppresses the generation of liver metastatic ascites in breast cancer via inhibiting NLRP3 inflammasome activation.
Jiang D; Liu X; Tan R; Zhu Y; Zhang L
Int J Mol Med; 2024 Jan; 53(1):. PubMed ID: 38063231
[TBL] [Abstract] [Full Text] [Related]
10. Clinical and functional analysis of the germline
Pinto EM; Ribeiro EMSF; Wang J; Phillips AH; Kriwacki RW; Zambetti GP
Cold Spring Harb Mol Case Stud; 2023 Dec; 9(4):. PubMed ID: 38050059
[No Abstract] [Full Text] [Related]
11. Liposomes Containing Zinc-Based Chemotherapeutic Drug Block Proliferation and Trigger Apoptosis in breast cancer Cells.
Siva M; Das K; Guha S; Sivagnanam S; Das G; Saha A; Stewart A; Maity B; Das P
ACS Appl Bio Mater; 2023 Dec; 6(12):5310-5323. PubMed ID: 37988654
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy of everolimus-based therapy in advanced triple-positive breast cancer: Experience from three cancer centers in China.
Tan Y; Jiang H; Ma F; Wang J; Zhang P; Li Q; Tian X; Xu B; Zhao W; Fan Y
Thorac Cancer; 2023 Dec; 14(34):3397-3405. PubMed ID: 37936567
[TBL] [Abstract] [Full Text] [Related]
13. The prognostic value of a combined immune score in tumor and immune cells assessed by immunohistochemistry in triple-negative breast cancer.
Choi JE; Lee JS; Jin MS; Nikas IP; Kim K; Yang S; Park SY; Koh J; Yang S; Im SA; Ryu HS
Breast Cancer Res; 2023 Nov; 25(1):134. PubMed ID: 37924153
[TBL] [Abstract] [Full Text] [Related]
14. An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response.
Dioken DN; Ozgul I; Yilmazbilek I; Yakicier MC; Karaca E; Erson-Bensan AE
Cancer Immunol Immunother; 2023 Dec; 72(12):4065-4075. PubMed ID: 37768345
[TBL] [Abstract] [Full Text] [Related]
15. Impact of inter-observer variability on first axillary level dosimetry in breast cancer radiotherapy: An AIRO multi-institutional study.
Leonardi MC; Pepa M; Zaffaroni M; Vincini MG; Luraschi R; Vigorito S; Morra A; Dicuonzo S; Mazzola GC; Gerardi MA; Zerella MA; Cante D; Petrucci E; Borzì G; Marrocco M; Chieregato M; Iadanza L; Lobefalo F; Valenti M; Cavallo A; Russo S; Guernieri M; Malatesta T; Meaglia I; Liotta M; Palumbo I; Marcantonini M; Mezzenga E; Falivene S; Arrichiello C; Barbero MP; Ivaldi GB; Catalano G; Vidali C; Giannitto C; Ciabattoni A; Meattini I; Aristei C; Orecchia R; Cattani F; Jereczek-Fossa BA
Tumori; 2023 Dec; 109(6):570-575. PubMed ID: 37688419
[TBL] [Abstract] [Full Text] [Related]
16. Synthesis, Structure, and Magnetic and Biological Properties of Copper(II) Complexes with 1,3,4-Thiadiazole Derivatives.
Lavrenova LG; Sukhikh TS; Glinskaya LA; Trubina SV; Zvereva VV; Lavrov AN; Klyushova LS; Artem'ev AV
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629205
[TBL] [Abstract] [Full Text] [Related]
17. Theoretical, in Vitro Antiproliferative, and in Silico Molecular Docking and Pharmacokinetics Studies of Heteroleptic Nickel(II) and Copper(II) Complexes of Thiosemicarbazone-Based Ligands and Pefloxacin.
Ahmed S; Mahendiran D; Bhat AR; Rahiman AK
Chem Biodivers; 2023 Sep; 20(9):e202300702. PubMed ID: 37528701
[TBL] [Abstract] [Full Text] [Related]
18. Anticancer activity of Ni(II) and Zn(II) complexes based on new unsymmetrical salophen-type ligands: synthesis, characterization and single-crystal X-ray diffraction.
Villaman D; Vega A; Santa Maria de la Parra L; León IE; Levín P; Toro PM
Dalton Trans; 2023 Aug; 52(31):10855-10868. PubMed ID: 37486008
[TBL] [Abstract] [Full Text] [Related]
19. PD-L2 overexpression on tumor-associated macrophages is one of the predictors for better prognosis in lung adenocarcinoma.
Matsubara E; Shinchi Y; Komohara Y; Yano H; Pan C; Fujiwara Y; Ikeda K; Suzuki M
Med Mol Morphol; 2023 Dec; 56(4):250-256. PubMed ID: 37402054
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic and predictive impact of gene expression in node-positive early breast cancer patients receiving dose-dense versus standard-dose adjuvant chemotherapy.
Reinisch M; Bruzas S; Gluz O; Ataseven B; Schmid P; Cortés J; Blohmer JU; Shenoy S; Dyson MH; Dittmer-Grabowski C; Chiari O; Harrach H; Gebauer D; Traut A; Kuemmel S
Mol Oncol; 2023 Jun; 17(6):1060-1075. PubMed ID: 37057719
[TBL] [Abstract] [Full Text] [Related]
[Next]
